Objective: To compare the retinal vascular network and structure of optic neuritis associated with myelin oligodendrocyte glycoprotein antibodies (MOG-ON) or aquaporin-4 antibodies (AQP4-ON).
Methods: Nineteen patients with MOG-ON (29 eyes), 24 patients with AQP4-ON (43 eyes), and 25 healthy participants (50 eyes) were enrolled. The best-corrected visual acuity (BCVA), mean deviation (MD), retinal nerve fiber layer (RNFL) thickness, parafoveal ganglion cell and inner plexiform layer (GCIPL) thickness, and vessel densities in the peripapillary and parafoveal areas were measured.
Results: The BCVA, RNFL thickness, GCIPL thickness, and vessel densities in the peripapillary and parafoveal areas were significantly decreased in the AQP4-ON and MOG-ON eyes compared with healthy controls (all P < 0.05). There were no significant differences in the MD, RNFL thickness, GCIPL thickness, or vessel densities between the AQP4-ON and MOG-ON eyes (all P > 0.05). However, the BCVA was significantly worse in AQP4-ON eyes than in MOG-ON eyes (P = 0.001). The peripapillary vessel density was significantly correlated with the BCVA and MD in AQP4-ON eyes and with MD in MOG-ON eyes (all P < 0.05).
Conclusions: MOG-ON and AQP4-ON are associated with severe visual dysfunction, as well as retinal structural and vascular damage. The extent of visual dysfunction was strongly correlated with the peripapillary vessel density. Although we found no significant difference in the MD between MOG-ON and AQP4-ON, which are characterized by comparable vascular and structural damage within the peripapillary and parafoveal areas, the BCVA was worse in AQP4-ON eyes than in MOG-ON eyes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00415-021-10609-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic Value of Inter-Eye Difference Metrics on OCT for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis.
Neurol Neuroimmunol Neuroinflamm
November 2024
From the Moorfields Eye Hospital NHS Foundation Trust (G.V., N.J., G.G.), London, United Kingdom; Department of Ophthalmology (G.V.), Institute of Clinical Neurosciences of Southern Switzerland (INSI), Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland; Department of Neuro-ophthalmology (N.J.), The National Hospital for Neurology and Neurosurgery, UCL Queen Square Institute of Neurology, The National Hospital for Neurology and Neurosurgery; Institute of Ophthalmology (N.J.), University College London, United Kingdom; Federal University of the State of Rio de Janeiro (UNIRIO) (G.G.), Brazil; Einstein Center for Digital Future Berlin (H.G.Z.); Experimental and Clinical Research Center (ECRC) (H.G.Z., S.M., C.B., A.U.B., F.P., F.C.O.), Max-Delbrueck-Center Berlin & Charité - Universitätsmedizin Berlin; Neuroscience Clinical Research Center (NCRC) (H.G.Z., S.M., C.B., A.U.B., F.P., F.C.O.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany; Centre for Advanced Neurological Research (L.P., A.D.C.), Nitte University, Mangalore, India; Department of Medicine (M.R.Y.), David Geffen School of Medicine at UCLA, Los Angeles; Divisions of Molecular Medicine and Infectious Diseases (M.R.Y.), Department of Medicine; Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles Medical Center (M.R.Y.), Torrance, CA; Departments of Ophthalmology and Visual Sciences (T.J.S.), Kellogg Eye Center; Division of Metabolism (T.J.S.), Endocrine and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor; Department of Pediatrics (L.J.C.), University of Utah; Department of Neurology (F.P., F.C.O.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany; National Hospital for Neurology and Neurosurgery (A.P.), University College London Hospitals NHS Foundation Trust, Moorfields Eye Hospital NHS Foundation Trust and Queen Square Dept. of Neuroinflammation, UCL, Queen Square Institute of Neurology, University College London, United Kingdom; and Neuro-ophthalmology Expert Centre (A.P.), Amsterdam University Medical Center, The Netherlands.
Article Synopsis
- The 2022 International Consortium for Optic Neuritis introduced new diagnostic criteria using optical coherence tomography (OCT) to better assess optic neuritis, with a particular focus on intereye difference metrics in patients with MOG-associated optic neuritis (MOG-ON).
- A multi-center study validated the diagnostic value of pre-established intereye difference cutoff values in 66 subjects, finding that metrics from the macular ganglion cell and inner plexiform layer (mGCIP) were most sensitive and specific for diagnosing MOG-ON.
- Results indicated that OCT-based intereye difference metrics had high diagnostic accuracy for MOG-ON, especially in cases of unilateral optic neuritis, suggesting these metrics could effectively distinguish affected individuals
Applicability of the New Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Diagnostic Criteria in an Israeli Cohort.
Isr Med Assoc J
August 2024
Department of Ophthalmology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel, Laboratory of Eye Research, Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune demyelinating disorder of the central nervous system. Optic neuritis (ON) is the most common clinical manifestation of MOGAD in adults. In 2023, new MOGAD diagnostic criteria were proposed, highlighting the importance of supplemental criteria when MOG-immunoglobulin G (IgG) titers are unavailable.
View Article and Find Full Text PDFA comparative study on anti-MOG and anti-AQP4 associated optic neuritis following mild COVID-19: insights from a Chinese single-center experience.
Front Neurol
June 2024
Department of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Background: Research on the relationship between mild COVID-19 and the subsequent development of isolated optic neuritis (ON) with antibodies specific to myelin oligodendrocyte glycoprotein (MOG-ON) and aquaporin 4 (AQP4-ON) is limited, particularly case-control studies that directly compare these conditions within the same affected population.
Methods: A retrospective analysis of initial MOG-ON and AQP4-ON cases during the COVID-19 peak and subsequent months. Patients were classified as possible COVID-19 related ON (PCRON) or non-COVID-19 related ON (NCRON).
How far should I manage acute optic neuritis as an ophthalmologist? A United Kingdom perspective.
Eye (Lond)
August 2024
The Medical Eye Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Optic neuritis (ON) is an inflammation of or around the optic nerve, frequently caused by infectious or immune-mediated inflammatory disorders. In the UK, its strongest association is with Multiple Sclerosis (MS), though the combined prevalence of other associated infectious and immune-mediated inflammatory diseases (I-IMID) is similar to that of MS-ON. Prompt identification and understanding of ON's underlying cause informs tailored management and prognosis.
View Article and Find Full Text PDFMOG antibody-associated optic neuritis.
Eye (Lond)
August 2024
Translational Neuroimmunology Group, Kids Neuroscience Centre and Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a demyelinating disorder, distinct from multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). MOGAD most frequently presents with optic neuritis (MOG-ON), often with characteristic clinical and radiological features. Bilateral involvement, disc swelling clinically and radiologically, and longitudinally extensive optic nerve hyperintensity with associated optic perineuritis on MRI are key characteristics that can help distinguish MOG-ON from optic neuritis due to other aetiologies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!